Search hospitals > Indiana > South Bend
Memorial Hospital of South Bend
Claim this profileSouth Bend, Indiana 46601
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Recurrence
388 reported clinical trials
5 medical researchers
Summary
Memorial Hospital of South Bend is a medical facility located in South Bend, Indiana. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Recurrence and other specialties. Memorial Hospital of South Bend is involved with conducting 388 clinical trials across 453 conditions. There are 5 research doctors associated with this hospital, such as Nibal Saad, Thomas Reid, MD, Muhammad O. Toor, and Nonyem A. Onujiogu.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderER positive
HER2 negative
Stage IV
Top PIs
Nibal SaadMemorial Hospital of South Bend4 years of reported clinical research
Expert in Cancer
Studies Lung Cancer
22 reported clinical trials
56 drugs studied
Thomas Reid, MDMemorial Hospital of South Bend2 years of reported clinical research
Studies Ovarian Cancer
Studies Cancer
23 reported clinical trials
49 drugs studied
Muhammad O. ToorMemorial Hospital of South Bend4 years of reported clinical research
Expert in Cancer
Studies Lung Cancer
21 reported clinical trials
55 drugs studied
Nonyem A. OnujioguMemorial Hospital of South Bend5 years of reported clinical research
Studies Serous Cystadenocarcinoma
Studies Adenocarcinoma
6 reported clinical trials
19 drugs studied
Clinical Trials running at Memorial Hospital of South Bend
Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Cancer
Ovarian Tumors
Bladder Cancer
Pancreatic Cancer
Pancreatic Carcinoma
Ovarian Cancer
Fallopian Tube Cancer
Radiation and HER2-Targeted Therapy
for Breast Cancer
This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.
Recruiting2 awards Phase 315 criteria
Targeted Therapy
for Solid Tumors
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with some genetic changes or abnormalities (mutations) may benefit from treatment that targets that particular genetic mutation. ComboMATCH is designed to match patients to a treatment that may work to control their tumor and may help doctors plan better treatment for patients with locally advanced or advanced solid tumors.
Recruiting1 award Phase 217 criteria
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Memorial Hospital of South Bend?
Memorial Hospital of South Bend is a medical facility located in South Bend, Indiana. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Recurrence and other specialties. Memorial Hospital of South Bend is involved with conducting 388 clinical trials across 453 conditions. There are 5 research doctors associated with this hospital, such as Nibal Saad, Thomas Reid, MD, Muhammad O. Toor, and Nonyem A. Onujiogu.
Where is Memorial Hospital of South Bend located?
**Memorial Hospital of South Bend**
- **Address:** 615 N Michigan St, South Bend, IN.
- **Parking:** Bartlett Parking Garage, 100 W Bartlett St, South Bend.
Who should I call to ask about financial aid or insurance network?
For Memorial Hospital of South Bend:
- **Financial Assistance and Insurance Departments**: For billing questions, call 574-256-9824 or 833-317-0625. For specific financial assistance inquiries, contact 574-647-7167.
What insurance does Memorial Hospital of South Bend accept?
Memorial Hospital of South Bend accepts a wide range of insurance plans, including but not limited to Aetna, Blue Cross Blue Shield, CIGNA, Florida Blue, Humana, Medicare, Medicaid, and United Healthcare. For a comprehensive list of accepted insurance plans, it is recommended to contact the hospital directly. This ensures you have the most current information regarding their insurance contracts.
What awards or recognition has Memorial Hospital of South Bend received?
Memorial Hospital of South Bend, affiliated with Beacon Health System, offers access to oncology clinical trials sponsored by the National Cancer Institute and Mayo Clinic. The South Bend Clinic Center for Research, associated with Memorial Hospital, is recognized for its published trial findings in prestigious medical publications.